Abbott (NYSE:ABT) announced today that it is developing a new biowearable for continuously monitoring both glucose and ketone levels. The all-in-one sensor has already garnered FDA breakthrough device designation and will be used in pivotal trials in 2023, with regulatory submissions to follow thereafter. Abbott Park, Illinois-based Abbott said in a news release that the […]
Auto-injectors
Diabeloop raises $74.9M Series C
Diabeloop announced today that it raised approximately $74.9 million (€70 million) in a Series C financing round. LBO France, a private equity player, led the financing round, while Terumo — with which Diabeloop has partnered since 2020 — also participated in the round. Innovacom joined LBO France and Terumo as new investors, according to a […]
Insulet breaks ground on $200M manufacturing facility in Malaysia
Insulet (Nasdaq:PODD) announced the groundbreaking of its new Omnipod manufacturing facility in Malaysia. Acton, Massachusetts–based Insulet’s Johor Bahru, Malaysia-based manufacturing facility will produce its Omnipod automated insulin delivery system and strengthen the company’s global manufacturing capabilities. The facility will include approximately 400,000 square feet of manufacturing space, with Insulet planning to invest approximately $200 million […]
Beta Bionics looks to reduce ‘cognitive burden’ for those with diabetes with bionic pancreas
Beta Bionics’ iLet bionic pancreas offers insulin therapy without some of the hurdles associated with treating diabetes. Users of insulin pumps may be used to a certain regimen associated with managing their diabetes. That can include carbohydrate counting, setting basal rates and more. Beta Bionics has set out to change that. With the Concord, Massachusetts-based […]
Dexcom quashes talk of Insulet merger, says discussions are not ongoing
Dexcom (Nasdaq:DXCM) today issued a statement denying recent rumors of a potential merger with Insulet (Nasdaq:PODD). Last week, reports circulated saying talks over a potential acquisition were ongoing, with an agreement between the two diabetes technology developers on the horizon in the coming weeks. On the back of the Dexcom statement, DXCM shares were up 7% at $308.87 apiece […]
Medtronic ‘hopeful’ on FDA clearance for next-gen diabetes tech in FY 2023
The Medtronic (NYSE:MDT) diabetes business sputtered in the fourth quarter but could be bolstered by a major regulatory nod this year. The Fridley, Minnesota-based company saw revenues for its diabetes arm fall by 7.7% year-over-year in the fourth quarter amid overall misses on both sales and adjusted earnings per share compared to Wall Street’s expectations. […]
Bigfoot Biomedical adds former Insulet VP as chief commercial officer
Bigfoot Biomedical announced today that it appointed former Insulet executive Matt Rainville as its chief commercial officer. Rainville’s role includes leading the growth of Milpitas, California–based Bigfoot Biomedical’s fully commercial Bigfoot Unity diabetes management program as the company looks to expand access to its offerings. Bigfoot Unity aims to simplify CGMs and the data they […]
Vivera picks up new patent for electronic dose-controlled drug delivery devices
Vivera announced today that it received a third U.S. patent for its Zicoh electronic dose-controlled drug delivery device portfolio. Newport Beach, California–based Vivera’s latest patent from the U.S. Patent and Trademark Office (USPTO) secures Zicoh’s rights as a smart dosing system with automated delivery, measurement, and management for oral format medications, including pills, capsules and […]
Report: Dexcom in talks to acquire Insulet
Major players in the diabetes space could join forces as Dexcom (Nasdaq:DXCM) is reportedly in discussions to acquire Insulet (Nasdaq:PODD). Bloomberg reported today that people “with knowledge of the matter” have said talks are ongoing over a potential acquisition and even said an agreement could be reached “in the coming weeks.” Bloomberg said its sources preferred […]
ApiJect picks up $111M investment from Royalty Pharma, Jefferies
Injection delivery system developer ApiJect announced today that it completed a private investment round worth $111 million. Royalty Pharma and Jefferies Financial Group led the investment round. Jefferies also acquired a revenue interest in addition to equity through the financing. According to a news release, the investment round values ApiJect at approximately $300 million. Jefferies […]